Screening for colorectal cancer: the role of the primary care physician.

Eur J Gastroenterol Hepatol

aInflammatory Bowel Disease Unit, 'IASO General' Hospital b2nd Propaedeutic Surgical Department, 'Laiko' Hospital, University of Athens, Athens cHealth Center of Kalivia, Kalivia, Attiki dExperimental-Research Laboratory, ELPEN Pharma, Athens, Greece.

Published: January 2017

In recent years, the role of primary care physicians (PCPs) in the diagnosis and management of gastrointestinal disorders, including screening for colorectal cancer (CRC), has been recognized as very important. The available data indicate that PCPs are not adequately following CRC screening guidelines because a number of factors have been identified as significant barriers to the proper application of CRC screening guidelines. These factors include lack of time, patient reluctance, and challenges related to scheduling colonoscopy. Further positive engagement of PCPs with CRC screening is required to overcome these barriers and reach acceptable levels in screening rates. To meet the expectations of modern medicine, PCPs should not only be able to recommend occult blood testing or colonoscopy but also, under certain conditions, able to perform colonoscopy. In this review, the authors aim to provide the current knowledge of the role of PCPs in increasing the rate and successfully implementing a screening program for CRC by applying the relevant international guidelines.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134820PMC
http://dx.doi.org/10.1097/MEG.0000000000000759DOI Listing

Publication Analysis

Top Keywords

crc screening
12
screening colorectal
8
colorectal cancer
8
role primary
8
primary care
8
screening guidelines
8
screening
7
pcps
5
crc
5
cancer role
4

Similar Publications

Lactylation of HDAC1 Confers Resistance to Ferroptosis in Colorectal Cancer.

Adv Sci (Weinh)

January 2025

Department of General Surgery, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine; National Experimental Teaching Center of Basic Medical Science, Department of Medical Genetics, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, 211166, China.

Colorectal cancer (CRC) is highly resistant to ferroptosis, which hinders the application of anti-ferroptosis therapy. Through drug screening, it is found that histone deacetylase inhibitor (HDACi) significantly sensitized CRC to ferroptosis. The combination of HDACi and ferroptosis inducers synergically suppresses CRC growth both in vivo and in vitro.

View Article and Find Full Text PDF

Background: Some cancers have been found to require abundant supplies of lipids for their development. One example is prostate cancer (PCa). To date, lipid-modifying factors, such as proprotein convertase subtilisin/kexin type 9 (PCSK9), angiopoietin-like 3 protein (ANGPTL3), and lipoprotein(a) or Lp(a), have not been reported in men with PCa.

View Article and Find Full Text PDF

Background: Compared to colorectal cancer (CRC) in adults, CRC in children is extremely rare. Although its incidence has increased recently, there is a lack of clinical research on the disease. Inherited cancer susceptibility syndromes (ICSS), a group of disorders in which patients are predisposed to susceptibility to a wide range of tumors as a result of pathogenic mutations in genes in their germ line, are an important cause of CRC in children.

View Article and Find Full Text PDF

Early-onset colorectal cancer (EOCRC) is an alarming entity worldwide. Yet, stage-specific characteristics and prognosis in localized and synchronous metastatic EOCRC are not well-defined. Two cohorts of CRC patients (localized and synchronous metastatic) were evaluated, defining EOCRC as the diagnosis <50 years old.

View Article and Find Full Text PDF

Lynch syndrome screening in colorectal and endometrial cancers in Iceland.

Acta Oncol

January 2025

University of Iceland, Faculty of Medicine, Reykjavik, Iceland; Department of Oncology, Landspitali University Hospital of Iceland, Reykjavik, Iceland.

Background And Purpose: Screening for Lynch syndrome (LS) with mismatch repair (MMR) protein immunohistochemistry (IHC) in all patients with newly diagnosed colorectal (CRC) and endometrial cancer (EC) was implemented in Iceland in 2017. The aim of the study is to assess the accuracy of screening in 2020-2022 and compare it to 2017-2019 when screening was initiated.

Patients/materials And Methods: All patients diagnosed with CRC and EC according to the Icelandic Cancer Registry in 2020-2022 were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!